drugset / Trial / NCT01927263

A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis

NCT01927263

Phase 3 Completed 242 enrolled Nichi-Iko Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate similarity between NI-071 and infliximab(the comparator) in terms of efficacy in patients with Rheumatoid Arthritis not adequately responding to Methotrexate.

Timeline

Start
2013-07
Primary completion
2015-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Infliximab Monoclonal antibody
Subject NI-071 Unknown

Indications